VANCOUVER, British Columbia, May 25, 2020 (GLOBE NEWSWIRE) — Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, continues to augment its board of directors through the appointment of accomplished business executives and thought leaders with successful track records of advancing research and awareness within the arena of depression, post-traumatic stress disorder (“PTSD”), and substance abuse disorders (“DPS”). To this accord, Champignon is pleased to appoint Dr. Bill Wilkerson, LL.D. (Hon) to its board of directors.
An executive equipped with extensive service in business, government, broadcasting, the arts, and corporate crisis management, Dr. Wilkerson is an 8-time award-winning pioneer in workplace mental health. He led a Canadian-based, international initiative from 1998 to 2012 to recruit major employers in support of employee mental health, introducing the phrase and concept of mental health in the workplace. Dr. Wilkerson was previously President of one of Canada’s largest health benefits companies, Liberty Health, and held senior executive positions at the Royal Bank of Canada, CBC, and the Toronto Symphony Orchestra.
Dr. Wilkerson has also been a business and communications adviser in the sports and entertainment sector having worked with the National Hockey League, the Hockey Hall of Fame, the Toronto Blue Jays, the Canadian Football League, TSN, CTV, and the Rogers Centre. Dr. Wilkerson initiated and chaired the U.S./Canada Forum on Mental Health and Productivity which rotated between Washington, Ottawa, Boston, Toronto, and Denver. Dr. Wilkerson also chaired a 4-year (2013-2017) business-led campaign throughout Europe called “Target Depression in the Workplace”, and the European Business Leadership Forum for Mental Health in the Workplace. He has travelled to more than twenty European capitals sharing his message with institutions as reputable and diverse as the European Central Bank and Royal Mail.
“I am pleased to join the board of directors of Champignon to help deploy, at long last, treatments of depression that work, work fast, restore health, fuel hope, animate workplace productivity, and save lives,” said Dr. Wilkerson. “The mission of this company is fundamental and enduring; to meet a pressing public need. This is what my twenty-two years of advocacy for mental health in the workplace has been all about. This directorship also permits me to support and help facilitate the vision of the extraordinarily skilled and dedicated physician-scientist Dr. Roger McIntyre, a world leader in a field that cries out for his kind of resolve, courage, compassion, and knowledge. I am humbled by, and grateful for, the opportunity to serve.”
Dr. Roger McIntyre, Chief Executive Officer of Champignon, commented: “We are thrilled to welcome Dr. Wilkerson to our board of directors. I look forward to working with him on a personal level as his decades of thought leadership in mental health and extensive global network will be vital to guiding our strategic initiatives and driving operational growth. As we forge a path forward, Dr. Wilkerson’s counsel and expertise will strengthen our mission-critical solutions to better serve our patients along with our employees and shareholders. I am a strong believer that the best processes have a people-centric vision front of mind. Dr. Wilkerson’s years of steadfast diligence and empathy in this space are a valued contribution to our efforts overall.”
The Company also announces the resignation of Mr. Joe Perino from its board of directors. Champignon thanks Mr. Perino for his contributions to date and wishes him the best of luck with his future endeavours.
About Champignon Brands Inc.
Champignon Brands (CSE: SHRM) is focused on the formulation and manufacturing of novel ketamine, anaesthetics, and adaptogenic delivery platforms for nutraceutical and psychedelic medicine while being supported by a leading psychedelics medicines clinic platform. The Company is pursuing the development and commercialization of rapid onset treatments capable of improving health outcomes, such as depression and post-traumatic stress disorder (PTSD), as well as substance and alcohol use disorders. Under a collaborative research agreement with the University of Miami’s Miller School of Medicine, the Company is conducting preclinical studies and eventual human clinical trials, with the objective of demonstrating safety and efficacy of the combination of psilocybin and cannabidiol in treating mTBI with PTSD or stand-alone PTSD. Champignon continues to be inspired by sustainability as its medicinal mushroom-infused SKUs are organic, non-GMO, and vegan certified. For more information, visit the Company’s website at: https://champignonbrands.com/.
ON BEHALF OF THE BOARD OF DIRECTORS
Dr. Roger McIntyre
Chief Executive Officer
FOR INVESTOR INQUIRIES:
T: +1 (833) 375-9995
FOR CHAMPIGNON BRANDS FRENCH INQUIRIES:
T: (888) 585-MARI
The CSE and Information Service Provider have not reviewed and does not accept responsibility for the accuracy or adequacy of this release.
Forward-looking Information Cautionary Statement
This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, statements we make regarding the speed and effectiveness of our treatments are “forward-looking statements.” Forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events, or developments to be materially different from any future results, events or developments expressed or implied by such forward looking statements. Such risks and uncertainties include, among others, the Company’s requirements for additional financing, and the effect of capital market conditions and other factors on capital availability, the Company’s limited operating history and lack of historical profits; competition; failure of treatments to provide the expected health benefits; unanticipated side effects; dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing federal, provincial, state, municipal, local or other licenses; developments and changes in laws and regulations, including increased regulation of the Company’s industries and the capital markets; economic and financial conditions; volatility in the capital markets; engaging in activities that could be later determined to be illegal under domestic or international laws; failure to obtain the necessary shareholder, government or regulatory approvals, including that of the CSE; failure to retain, secure and maintain key personnel and strategic partnerships including but not limited to executives, researchers, clinicians, customers and suppliers; These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, which are available at www.sedar.com. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company has no obligation to update any forward-looking statement, even if new information becomes available.
Published at Mon, 25 May 2020 14:51:04 +0000